This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the treatment of severe, uncontrolled asthma in people aged 12 and older. The results of these 2 studies, called PATHWAY and NAVIGATOR, formed the basis for tezepelumab’s approval for use. Tezepelumab is a type of biologic treatment called an antibody. It works by blocking a key first step in the body’s chain reaction leading to inflammation in the airways of people with severe asthma.The clinical studies were done to learn if tezepelumab can be used to treat people with severe, uncontrolled asthma and to find out about its safety. In both studies, tezepelumab was compared with the placeboThis Plain Language Summary of Publication article from Immunotherapy discusses the results of two studies called PATHWAY and NAVIGATOR. These studies formed the basis for a medication called tezepelumab to be approved to treat people with severe asthma aged 12 and older in the USA, EU and other countries.

Visit the Future Medicine site using the link to read the article.

The PATHWAY and NAVIGATOR articles that this summary is based on are called ‘Tezepelumab in adults with uncontrolled asthma’ and ‘Tezepelumab in adults and adolescents with severe, uncontrolled asthma’, respectively. Both articles were published in the New England Journal of Medicine. 

You can both articles by visiting the New England Journal of Medicine website using the following links.